Use of triazoles for the treatment of invasive aspergillosis: A three‐year cohort analysis

Summary In a 3‐year cohort study of adult patients with proven or probable IA, fewer patients initially treated with isavuconazole experienced adverse events compared with voriconazole, but more patients required a change in therapy due to lack of clinical efficacy.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Mycoses 2020-01, Vol.63 (1), p.58-64
Hauptverfasser:	Cheng, Matthew P., Orejas, José L., Arbona‐Haddad, Esther, Bold, Tyler D., Solomon, Isaac H., Chen, Kaiwen, Pandit, Alisha, Kusztos, Amanda E., Cummins, Kaelyn C., Liakos, Alexis, Marty, Francisco M., Koo, Sophia, Hammond, Sarah P.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antifungal Agents - therapeutic use Aspergillosis Aspergillosis - drug therapy Aspergillus Cohort analysis Cohort Studies Female Humans invasive aspergillosis Invasive Fungal Infections - drug therapy isavuconazole Male Middle Aged Nitriles - adverse effects Nitriles - therapeutic use Patients posaconazole Pyridines - adverse effects Pyridines - therapeutic use Treatment Outcome Triazoles Triazoles - adverse effects Triazoles - therapeutic use Voriconazole Voriconazole - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Summary In a 3‐year cohort study of adult patients with proven or probable IA, fewer patients initially treated with isavuconazole experienced adverse events compared with voriconazole, but more patients required a change in therapy due to lack of clinical efficacy.
ISSN:	0933-7407 1439-0507
DOI:	10.1111/myc.13013